Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of elranatamab versus lenalidomide after autologous stem cell transplant in newly diagnosed multiple myeloma
MOH_2022-03-09_010665Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Elranatamab with Lenalidomide (2 arms). Started Mar 2022; status: recruiting.
02
Drugs
elranatamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-03-09_010665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-09_010665.